GONDOLA MEDICAL TECHNOLOGIES SA

Their core work

Gondola Medical Technologies develops a medical device — the GONDOLA system — that applies automated mechanical stimulation to specific anatomical points on the feet to improve gait and balance in people with neurological conditions, primarily Parkinson's disease. The core technology, Automated Mechanical Peripheral Stimulation (AMPS), works by activating neural pathways through peripheral sensory input rather than electrical stimulation, offering a non-invasive rehabilitation tool. Their work spans from early feasibility validation through clinical demonstration and commercialisation, following the full EU SME Instrument pathway. They sit at the intersection of neurology, rehabilitation engineering, and medical device development.

What they specialise in

How they've shifted over time

Gondola followed the EU SME Instrument two-step pathway almost textbook-perfectly: a small EUR 50,000 Phase 1 feasibility grant in 2018-2019 to validate the AMPS concept for Parkinson's motor rehabilitation, followed by a EUR 2.49M Phase 2 demonstration award in 2020-2022 to develop and validate the device for the broader neurological market. The shift is not a change in technology direction — AMPS remains the core — but a deliberate widening of the clinical indication from Parkinson's specifically to all neurological walking and balance disabilities, which substantially enlarges the addressable market. This is a company that has executed a focused, disciplined product development arc rather than pivoting or diversifying.

Gondola is on a commercialisation trajectory — having completed Phase 2 funding by 2022, they are most likely seeking clinical partnerships, CE marking, and market entry in European neurology and rehabilitation clinics rather than additional research grants.

How they like to work

Gondola has operated exclusively as project coordinator across both H2020 projects, which is characteristic of SME Instrument funding where a single company leads the innovation. Their recorded partner count is zero — the SME Instrument structure allows solo applications, and their data reflects this self-contained approach. Anyone engaging them as a consortium partner should expect a company that is used to leading its own agenda; they are likely most valuable as a technology provider or clinical use-case anchor in a larger consortium rather than as a passive participant.

Gondola's recorded H2020 network is essentially non-existent in consortium terms — zero documented partners, reflecting the solo-company SME Instrument model they used for both projects. Their real network likely exists through clinical trial sites, neurology departments, and rehabilitation centres rather than formal H2020 consortium relationships.

What sets them apart

Gondola occupies a narrow but well-defined niche: mechanical (not electrical) peripheral stimulation for neurological gait disorders — a modality with a different safety and usability profile from transcranial or electrical nerve stimulation devices. As a Swiss SME with Phase 2 EU validation behind them, they bring a clinically-tested, investment-ready device platform that few companies in this space can match at this development stage. For consortium builders in neurorehabilitation, they represent a rare case of a fully-controlled proprietary technology with documented EU-backed clinical development.

Highlights from their portfolio

• GONDOLA AMPS
  At EUR 2.49M, this is one of the larger EU SME Phase 2 medical device awards and signals a transition from proof-of-concept to full clinical and commercial development for a neurological walking disorder platform.
• GONDOLA
  The EUR 50,000 SME Phase 1 feasibility project validated the mechanical peripheral stimulation concept for Parkinson's — the foundational step that unlocked the much larger follow-on award.